Idera Starts Phase I Trial for Hepatitis C Drug
Posted on: Wednesday, 19 September 2007, 09:02 CDT
Idera Pharmaceuticals has dosed the first patient in a Phase I trial evaluating its hepatitis C treatment.
IMO-2125 is a novel agonist of toll-like receptor 9. The trial is designed to assess the safety and tolerability of IMO-2125 at different dose levels as well as determine the effect of IMO-2125 on HCV RNA levels and parameters of immune system activation.
Sudhir Agrawal, CEO and CSO, said: "IMO-2125 is a TLR9 agonist that Idera designed to induce endogenous interferon-alpha along with other immune response factors to treat hepatitis C. IMO-2125 is the second novel TLR9 agonist from our portfolio to enter the clinic following IMO-2055 for cancer.
"We generated both of these drug candidates using our chemistry-based drug discovery approach which allows us to design TLRtargeted drug candidates which act as agonists for TLR7, 8 or 9 or as TLR antagonists for a broad spectrum of indications."
Robert Karr, president, said: "The preclinical data that we have generated, including data demonstrating potency in the HCV replicon assay of cytokines and chemokines present in the blood of non-human primates treated with IMO-2125, provides a strong rationale for evaluating IMO-2125 in patients with HCV infection."
The Phase I trial evaluating IMO-2125 is being conducted in HCV patients who have failed to respond to previous combination therapy with ribavirin and pegylated interferon-alpha. Four doses of IMO-2125 are being investigated. IMO-2125 will be administered subcutaneously once a week and treatment will continue for four weeks. The target enrollment for the trial is 40 patients with ten patients per cohort. Of the ten patients per cohort, eight are randomized to receive IMO-2125 treatment and two are randomized to receive placebo treatment.
Source: Datamonitor
Related Articles
- Clinical Center of Serbia, Institute for Cardiovascular Diseases Treats First Patient in Trial of Pioneering Stem Cell-Derived Therapy for Heart Failure
- KaloBios Completes Patient Dosing in Its U.S. Phase 1 Trial of Its Third Drug Candidate, KB003
- BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known As Karenitecin(R)
- Idera Pharmaceuticals Presents Preclinical Data on IMO-2125 and Other TLR9 Agonists
- Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C
- Samaritan Announces Positive Preliminary Results in a Phase IIb Study For Its Novel Oral HIV Entry Inhibitor; SP01A Being Developed As an Adjunct Treatment for 'HIV Drug Resistance' Has Demonstrated Efficacy in Three Phase II Clinical Trials
- Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
- China Focus: Chinese AIDS Patients Longing for Better Anti-Viral Drugs
- Bone Marrow Transplant Patient Accepts New Kidney Without Taking Drugs
- Metabolic Pharmaceuticals Initiates Recruitment for Phase II-B Clinical Trial of AOD9604 Obesity Drug
 |
 |
User Comments (0)
RSS Feeds